MiMedx Group (MDXG) Reports Q4 EPS of 12c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
MiMedx Announces 2015 Record Results
February 23, 2016 7:30 AM ESTMARIETTA, Ga., Feb. 23, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today its record results for the full year and fourth quarter ended December 31, 2015.
Full Year 2015 Highlights are:
4th consecutive year of meeting or exceeding revenue guidance Revenue of $187.3 million increased by 58% over 2014 Revenue... More